Subtype
Neuroblastic Tumor
CI-CAN-00001274Explore in graph →
137 active trials3 approved drugs28 evidence items
- NCIt
- C6963
Loading cancer entity…
Subtype
CI-CAN-00001274Explore in graph →
Clinical trials
619 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (80)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07819838 | Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations | not yet recruiting | Phase 1 / Phase 2 | 77 | Children's Oncology GroupNETWORK | 0 | Sep 15, 2026 | clinicaltrials |
| NCT07437963 | Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse | not yet recruiting | Phase 1 / Phase 2 | 76 | National Cancer Institute (NCI)NIH | 0 | Sep 9, 2026 |
| clinicaltrials |
| NCT04637503 | 4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma | not yet recruiting | Phase 1 / Phase 2 | 100 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07261241 | NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab | not yet recruiting | Phase 2 | 118 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07527169 | A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma | not yet recruiting | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07111117 | Comparison of 18F Labeled Analog of MIBG (18F-MFBG) PET/CT and 123I-MIBG SPECT in Pediatric Patients With Neuroblastoma.(NEUROBLASTOTEP) | not yet recruiting | Phase 2 | 30 | Institut CurieOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT06948994 | A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Diagnosed High-risk or Relapsed/Refractory Neuroblastoma | not yet recruiting | Phase 1 / Phase 2 | 15 | Guangzhou Women and Children's Medical CenterOTHER | 0 | Apr 29, 2025 | clinicaltrials |
| NCT05303727 | Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma | not yet recruiting | Phase 2 | 64 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 1, 2022 | clinicaltrials |
Data updated 15 days agoSource updated Sep 15, 2026source: clinicaltrials